MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

Search

Relay Therapeutics Inc

Затворен

СекторЗдравеопазване

3.51 -2.23

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.47

Максимум

3.58

Ключови измерители

By Trading Economics

Приходи

-1.1M

-77M

Продажби

7.7M

7.7M

Марж на печалбата

-1,003.581

Служители

259

EBITDA

-1.2M

-85M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+247.75% upside

Дивиденти

By Dow Jones

Следващи печалби

5.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

56M

610M

Предишно отваряне

5.74

Предишно затваряне

3.51

Настроения в новините

By Acuity

50%

50%

154 / 376 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Relay Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.07.2025 г., 23:41 ч. UTC

Пазарно говорене

Nikkei May Trade in Range Amid Tariff Uncertainty -- Market Talk

15.07.2025 г., 23:40 ч. UTC

Пазарно говорене

Gold Edges Higher on Possible Position Adjustments -- Market Talk

15.07.2025 г., 23:05 ч. UTC

Пазарно говорене

Auckland International Airport Passenger Growth May Disappoint Again -- Market Talk

15.07.2025 г., 21:36 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

15.07.2025 г., 21:36 ч. UTC

Пазарно говорене

Canada CPI Data Fuel Rate-Prediction Revisions -- Market Talk

15.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

15.07.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Financial Services Roundup: Market Talk

15.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

15.07.2025 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

15.07.2025 г., 20:14 ч. UTC

Придобивния, сливания и поглъщания

Chinese EV Makers to Combine. Geely Is Buying Zeekr. -- Barrons.com

15.07.2025 г., 20:07 ч. UTC

Печалби

BlackRock Shares Tumble After Big Client Redemption Blunts Quarterly Results -- Update

15.07.2025 г., 20:06 ч. UTC

Пазарно говорене

Nvidia, AMD Seen Benefiting from Return to Chinese Chip Sales -- Market Talk

15.07.2025 г., 19:54 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

15.07.2025 г., 19:54 ч. UTC

Пазарно говорене

Meta CEO Hints at Higher Revenues, Expenses With Data Center Plans -- Market Talk

15.07.2025 г., 19:38 ч. UTC

Пазарно говорене

Oil Falls As Eventual Oversupply Concerns Weigh -- Market Talk

15.07.2025 г., 19:09 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Back-to-Back Gains -- Market Talk

15.07.2025 г., 19:07 ч. UTC

Пазарно говорене

Canada CFOs Willing to Take Risks, Increase Spending -- Market Talk

15.07.2025 г., 19:03 ч. UTC

Пазарно говорене

Gold Slips as Big Buyers Pull Back -- Market Talk

15.07.2025 г., 18:32 ч. UTC

Придобивния, сливания и поглъщания

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15.07.2025 г., 18:31 ч. UTC

Придобивния, сливания и поглъщания

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

15.07.2025 г., 18:13 ч. UTC

Пазарно говорене

Canada Adopts 'Note of Realism' in US Trade Talks, Setting Stage for Possible Tariff Deal -- Market Talk

15.07.2025 г., 17:40 ч. UTC

Пазарно говорене

Canadian Inflation Adds to Case for Bank of Canada Extending Pause -- Market Talk

15.07.2025 г., 17:40 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

15.07.2025 г., 17:25 ч. UTC

Придобивния, сливания и поглъщания

National Fuel Gas Gets Rare Double Upgrade. Buy the Stock, Analyst Says. -- Barrons.com

15.07.2025 г., 17:24 ч. UTC

Пазарно говорене

Dollar Gains Strength After Inflation Data -- Market Talk

15.07.2025 г., 16:49 ч. UTC

Пазарно говорене

Oil Futures Likely to Continue Sideways Trade -- Market Talk

15.07.2025 г., 16:20 ч. UTC

Пазарно говорене
Печалби

Financial Services Roundup: Market Talk

15.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

15.07.2025 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

15.07.2025 г., 15:42 ч. UTC

Пазарно говорене

Coca-Cola Seen as Top Pick Ahead of Consumer Staples Earnings -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Relay Therapeutics Inc Прогноза

Ценова цел

By TipRanks

247.75% нагоре

12-месечна прогноза

Среден 12.38 USD  247.75%

Висок 17 USD

Нисък 4 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Relay Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

8

Купи

2

Задържане

0

Продай

Техническа оценка

By Trading Central

2.88 / 3.285Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

No Evidence

Настроение

By Acuity

154 / 376 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Среден

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.